|
 COLLABORATION OPPORTUNITY
Combination of Vaccine with Adoptive Cell Therapies Made at NCI for the Treatment of Cancer
Opportunity Overview
The NCI Surgery Branch is seeking a partner to provide a GMP-grade vaccine against cancer neo-antigens either private (patient-specific neo-antigens) or shared common tumor antigens (such as KRAS or P-53). The goal: A phase-1 human clinical trial for solid cancers.
- Collaborate with researchers at the NCI Surgery Branch to co-develop the combination of NCI-engineered cell therapies with a vaccine to be provided by the partner.
- Vaccine would target the same neo-antigens found in the engineered peripheral blood lymphocytes (PBL) or tumor infiltrating lymphocytes (TIL) which will be isolated and characterized using NCI proprietary methods.
NCI Surgery Branch Contributions to Collaboration
- Extensive expertise in the latest technology of TIL development, as well as T-cell receptor (TCR) -transduced PBL development using NCI proprietary methodologies.
- Ability to provide GMP-Grade TIL’s or PBL’s to be combined with the vaccine.
- Recruitment of patients and conduct of trial at NCI.
Needed Collaborator Capabilities
- An industry partner with expertise in this area of vaccine manufacture to provide the GMP-grade vaccine to be used in combination with the NCI engineered T cells.
Next Steps
If you are interested in learning more about this partnering opportunity, please contact Aida.Cremesti@nih.gov, Senior Technology Transfer Manager, NCI Technology Transfer Center.
|
|
|
|
